Daiken Medical Co Ltd

Daiken Medical maintains a conservative capital structure with a debt-to-equity ratio of 0.27, significantly below the industry median of 0.55, and holds ¥2.996 billion in cash and equivalents, representing 26.8% of total assets. The company's liquidity position is strong, with a current ratio of 2.47, well above the industry median of 1.85. Profitability metrics show a return on equity (ROE) of 14.6%, outperforming the industry median of 10.2%, and a return on assets (ROA) of 9.82%, exceeding the sector median of 7.1%. Gross margin of 41.2% (¥4.097 billion gross profit on ¥9.952 billion revenue) aligns with the industry median of 40.8%, but operating margin of 15.2% (¥1.51 billion operating income) is 200 bps above the sector average. The company's revenue is concentrated in five product segments: suction devices (28% of revenue), syrinjectors (25%), electric pumps (19%), medical hand washing machines (17%), and other products (11%). Geographically, 93% of revenue is derived from Japan, with the remaining 7% from Asia-Pacific and European markets. Revenue growth has been stable, with a 4.8% year-over-year increase in FY2023 to ¥9.95 billion. Analysts project 3.2% growth in FY2024, driven by expansion in infection control product lines and increased adoption of PCA devices in hospital settings. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no near-term debt maturities and maintains a conservative leverage profile. Dilution potential is minimal, with basic and diluted shares outstanding aligned at 28.7 million shares. Recent events include a ¥619.8 million free cash flow generation in FY2023, with capital expenditures of ¥167.6 million primarily directed toward automation of production lines for syringe pumps. The company also announced a ¥3.0 billion share repurchase program in Q3 2023, reflecting confidence in its cash position and long-term value.